The global CRISPR and Cas Genes marketis expected to grow at the highest CAGR of 16.02% from 2020 – 2027 and the market is projected to generate $ 4.23 billion by 2027.
Precedence Research, Recently Published Report on “CRISPR and Cas Genes Market Size, Share, Growth, Trends, Segment Forecasts, Regional Outlook 2020 - 2027”. The report offers an up-to-date analysis regarding the current market scenario, latest trends, key drivers, potential challenges, profitability graph and the overall market environment.
One of the most ground-breaking improvements in biology sector has its origins in the RNA-based defense system of bacteria, that encrypts CRISPR-associated shortened as Cas with clustered recurrently interspaced short palindromic repeats abbreviated as CRISPR proteins. It has been adapted to work as a programmable genome-engineering tool that has empowered stress-free manipulation and targeting of specific genomic sequences in fungi, plants, bacteria, and mammals, comprising humans. CRISPR possess capability to develop an alternate biotechnology treatment for appending or alternative for the prevailing single-antibody drugs.
CRISPR technology is a modest yet influential tool for genome editing. It permits researchers to effortlessly modify DNA sequences and alter gene function. Its various budding applications comprise averting and treating the spread of ailments, improving genetic defects, and refining crops.
Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1108
Growth Factors
Progressions in the arena of genome editing have eased augmented adoption of CRISPR-Cas systems in diagnostics and in the valuation of evolutionary study in prokaryotes. This method is precisely utilized to comprehend the evolution of bacteria. Government organizations across the world have stimulated spending for genome editing developments thereby offering alluring growth prospects for global CRISPR and Cas genes market growth. The diversity of existing Cas proteins and elasticity of guide RNA production creates this practice a prevailing system for all genome editing applications. Also, the cumulative funding allotted for the genomics research and biotechnology development projects are further pushing the growth market throughout the forecast period.
Cumulative focus on development of innovative therapeutics on account of emergent pervasiveness of different genetic ailments and cancer is key influence projected to stimulate the progress of CRISPR and Cas genes marketplace during years to come. At present, gene editing landscape is also observing significant boost with several companies utilizing dissimilar versions of CRISPR-Cas along with corporations chasing alternative modalities with precise recompenses. This is because of the great amount of fundamental findings in basic gene editing. CRISPR-based discovery of nucleic acids is measured to be a profound, detailed, and trustworthy approach. Additionally, this technique needs testing to be done at a persistent temperature and eradicates the necessity of costly PCR platform.
Regional Snapshots
In 2019, North America conquered the whole CRISPR and Cas genes sector on account of reasons including occurrence of key companies, snowballing finance in genomics and biotechnology programs, and proven healthcare infrastructure among others. Augmented spending for research activities to offer reformed products for averting chronic diseases is predicted to push the progress of CRISPR and Cas genes market in North America. U.S. has the prevalent revenue contribution on account of reassuring healthcare policies, established healthcare sector and the high prevalence of chronic illnesses.
Asia Pacific is estimated to perceive the firmest development over the prediction period. China possesses a noteworthy footprint in the global CRISPR market arena and is progressively discovering genome-editing for the improvement of medicines. It has introduced numerous CRISPER-based clinical trials, particularly for treatment of cancer. Escalating requirement for genetically engineered treatment selections for chronic ailments including cancer is predicted to improve growth scenarios of the CRISPR market in Asia Pacific.
Key Players & Strategies
Global CRISPR and Cas genes marketplace is reasonably competitive and comprise numerous major companies. Particular players contending in this industry are Caribou Biosciences, Inc., Editas Thermo Fisher Scientific, Takara Bio Inc, OriGene Technologies, Inc., Merck KGaA, Horizon Discovery Ltd., Addgene, Medicine, Crispr Therapeutics, and Mirus Bio LLC amongst others.
Crucial performers in the CRISPR and CAS gene sector are converging on associations with numerous corporations for subsidizing clinical trials. For illustration, Editas Medicine licensed patent rights for CRISPR and other gene-editing from Harvard University, the Broad Institute, the MIT, and others. In March 2017, Editas collaborated with Allergan which is Irish pharmaceutical company. Under which Editas received around USD 90 million up-front payment for an choice to license up to 5 preclinical programs aiming eye disease.
Report Highlights
- North America led the global market revenue with a stake of more than 36% in 2019. Factors accountable for this enormous growth include involvement of pharmaceutical enterprises in the expansion of novel therapeutics by installing genome editing protocols
- At present, U.S. has the highest number of CRISPR publications across the globe, and endures to have the prevalent repository of cited papers.
- A substantial amount of research studies conducted to progress disease-specific innovative therapies and existence of a enormous clinical pipeline that incorporates the application of gene-editing technology are anticipated to upsurge revenue generation for pharmaceutical and the biotechnology companies segment of the market
Market Segmentation
By Product & Service
- By Service
- Microbial Gene Editing
- Cell Line Engineering
- gRNA Design
- DNA Synthesis
- By Product
- Design Tool
- Kits & Enzymes
- Libraries
- Antibodies
- Others
By Application
- Agricultural
- Biomedical
- Functional Genomics
- Genome Engineering
- Disease Model Studies
- Epigenetics
- Others
- End-use Outlook
- Contract Research Organizations (CROs),
- Academics & Government Research Institutes
- Biotechnology & Pharmaceutical Companies
By Regional Outlook
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Middle East & Africa
- Latin America
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global CRISPR & Cas Genes Market, By Product & Service
7.1. CRISPR & Cas Genes Market, by Product & Service Type, 2020-2027
7.1.1. Service
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Product
7.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global CRISPR & Cas Genes Market, By Application
8.1. CRISPR & Cas Genes Market, by Application, 2020-2027
8.1.1. Agricultural
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Biomedical
8.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global CRISPR & Cas Genes Market, By End-Use
9.1. CRISPR & Cas Genes Market, by End-Use, 2020-2027
9.1.1. Contract Research Organizations (CROs)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Academics & Government Research Institutes
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Biotechnology & Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 10. Global CRISPR & Cas Genes Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
Chapter 11. Company Profiles
11.1. Caribou Biosciences, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. F. Hoffmann-La Roche Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cellectis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Editas Medicine, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Addgene
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Egenesis
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Horizon Discovery Group Plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Intellia Therapeutics, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Genscrip
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Danaher Corporation
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Lonza
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Merck KGaA
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. Synthego
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. Mammoth Biosciences
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
11.16. Inscripta, Inc.
11.16.1. Company Overview
11.16.2. Product Offerings
11.16.3. Financial Performance
11.16.4. Recent Initiatives
11.17. Cibus
11.17.1. Company Overview
11.17.2. Product Offerings
11.17.3. Financial Performance
11.17.4. Recent Initiatives
11.18. New England BioLabs
11.18.1. Company Overview
11.18.2. Product Offerings
11.18.3. Financial Performance
11.18.4. Recent Initiatives
11.19. Takara Bio, Inc.
11.19.1. Company Overview
11.19.2. Product Offerings
11.19.3. Financial Performance
11.19.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1108
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 774 402 6168
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
0 Comments